GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Forward PE Ratio

American Cryostem (American Cryostem) Forward PE Ratio : 0.00 (As of May. 14, 2024)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem Forward PE Ratio?

American Cryostem's Forward PE Ratio for today is 0.00.

American Cryostem's PE Ratio without NRI for today is 0.00.

American Cryostem's PE Ratio for today is 0.00.


American Cryostem Forward PE Ratio Historical Data

The historical data trend for American Cryostem's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem Forward PE Ratio Chart

American Cryostem Annual Data
Trend
Forward PE Ratio

American Cryostem Quarterly Data
Forward PE Ratio

Competitive Comparison of American Cryostem's Forward PE Ratio

For the Biotechnology subindustry, American Cryostem's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Cryostem's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Cryostem's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where American Cryostem's Forward PE Ratio falls into.



American Cryostem Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


American Cryostem  (OTCPK:CRYO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


American Cryostem Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of American Cryostem's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915